Safety event delays US market approval of...Top-Line Phase 3 data of Amgen’s/UCB’s osteoporosis antibody romosozumab in postmenopausal women suggest efficacy but uncover a new safety signal. more ➔
Vesalius Biocapital fund raises €65mLuxembourg-based venture capital specialist Vesalius Biocapital has closed the first round of Biocapital III fund that aims to invest into later-stage European life sciences companies. more ➔
Merck presents new CRISPR genome editing m...German Merck KGaA has developed a new genome editing tool dubbed proxy-CRISPR providing access to previously inaccessible microenviroments of the genome by modification of chromatin modifications.&n … more ➔
Astellas completes Ogeda takeoverAstellas Pharma Inc. has completed the acquisition of Ogeda SA (previously Euroscreen SA, Gosselies, Belgium). more ➔
Vifor Pharma acquires US$50m share in Akeb...Swiss Vifor Pharma has agreed to acquire shares of Cambridge-based distributor Adebia worth US$50m in order exclusivly distribute its hypoxia-inducible factor (HIF) stabiliser vadadustat to 40% of US … more ➔
NSCLC: AstraZeneca’s durvalumab meet...AstraZeneca’s anti PD-L1 antibody durvalumab has met the co-primary endpoint in non-small cell lung cancer (NSCLC) in a Phase III trial vs placebo. OS data were not yet available. more ➔
Norgine to acquire Merus Dutch Norgine BV will take-over Merus Labs International Inc. Under the agreement, Norgine will acquire all outstanding shares for US$1.65 per share in cash. more ➔
Cheap Avastin as effective as Eylea in CRV...A study conducted by an NIH institute proves Roche’s Avastin is as effective as Regeneron’s Eylea, a drug that costs 30 times more than Roche’s antibody. The rub: Avastin is not approved for use in central … more ➔
Roche’s anti-PD-L1 fails in bladder...Fiasco in Phase III: Roche’s conditionally approved PD-L1 checkpoint inhibitor did not meet the endpoint of overall survival vs chemotherapy in a confirmatory study with pre-treated patients with metastatic … more ➔
Dermtreat bags €16.2m financingMucosal inflammation specialist Dermtreat ApS (Copenhagen) has secured a Series A financing worth €16.2m (US$17.7m). more ➔
